Madrigal Pharmaceuticals Inc (MDGL)

$109.04 4.96 (4.35%)

16:57 EST MDGL Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 1.55B

PE Ratio -43.79

EPS -2.49

Volume (Avg. Vol.) 147,739

Day's Range 108.61 - 115.93

52-Week Range 56.82 - 137.28

Dividend & Yield N/A (N/A)

MDGL Stock Predictions, Articles, and Madrigal Pharmaceuticals Inc News

From InvestorPlace
From the Web

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

By Aaron Levitt, InvestorPlace Contributor Sep 26, 2018

Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.

4 Biotech Stocks With Leaky Pipelines

By Regina Borsellino Apr 10, 2018

A strong pipeline can make or break biotech stocks, ensuring strong profits for years to come. These four biotech companies don't make the cut.

A Buy the Dip Stock Trigger in Madrigal Pharmaceuticals Inc

From Capital Market Laboratories Jan 14, 2021

The Techncial Trigger Driven Stock Trade in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) .

The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations

From Benzinga Nov 13, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (...

10 Biggest Price Target Changes For Friday

From Benzinga Nov 6, 2020

B of A Securities lowered the price target for Ollie's Bargain Outlet Holdings Inc (NASDAQ: OLLI) from $125 to $115. Ollie's Bargain shares rose 0.7% to $90.85 in pre-...

Pre-earnings Momentum Trade With a Technical Trigger in Madrigal Pharmaceuticals Inc

From Capital Market Laboratories Oct 23, 2020

The Techncial Trigger Driven Option Trade Right Before Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Earnings.

The Exact Trigger that Indicates Volatility in Madrigal Pharmaceuticals Inc

From Capital Market Laboratories Sep 1, 2020

The Trigger That Turned Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Volatility into a Winner.

The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions

From Benzinga Nov 8, 2020

Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy